In August 2025, Citest Diagnostics released a groundbreaking series of rapid diagnostic tests for Vibrio cholerae, targeting the major serotypes (O1 Inaba, O1 Ogawa, and O139) behind deadly cholera outbreaks. These fecal-based tests aim to revolutionize cholera detection, supporting epidemiological surveillance, vaccine research and infection control—especially in regions with constrained medical resources.
The product lineup encompasses three specialized assays: the Vibrio Cholerae O1 Inaba Rapid Test (IVCAI-CT602), which qualitatively detects the O1 Inaba serotype via chromatographic immunoassay to support rapid identification of infections linked to this strain, enabling timely clinical action; the Vibrio Cholerae O1 Ogawa Rapid Test (IVCAO-CT602), targeting the O1 Ogawa serotype and designed to address detection needs in regions where this prevalent variant circulates, bolstering localized epidemic surveillance; and the Combo Rapid Test (IVC-CT635), which simultaneously screens for Vibrio Cholerae O139, O1 Ogawa and O1 Inaba. This multi-serotype design eliminates the need for separate tests, streamlining diagnostic workflows and accelerating outbreak response decisions. All tests adopt a cassette format, simplifying sample analysis across clinical and field environments.
These tests deliver core advantages in speed, simplicity and reliability: rapid results within 10 minutes enable prompt intervention during outbreaks; easy-to-read cassette lines simplify interpretation for non - specialists, proving ideal for resource - limited environments; advanced immunochromatographic technology ensures robust performance, while a 2–30°C storage range boosts usability across diverse climates; and the cassette design minimizes hands - on time, facilitating efficient testing even in low - infrastructure regions.
In conclusion, Citest’s new Vibrio cholerae tests redefine infectious disease diagnostics by blending speed, precision and accessibility. By addressing the urgent need for rapid serotype differentiation, these tools strengthen outbreak response and public health strategies worldwide. This launch reflects Citest’s commitment to developing innovative solutions that safeguard communities—especially where cholera poses the greatest threat.
